OncoMatch/Clinical Trials/NCT06216938
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Is NCT06216938 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Vusolimogene oderparepvec (RP1) for melanoma.
Treatment: Vusolimogene oderparepvec (RP1) — This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells and does not infect healthy cells. This results in tumor cell lysis and the release of virus particles which infect and replicate within nearby tumor cells, resulting in tumor cel death. The immune system is activated by the released tumor-associated antigens (TAAs) from the tumor cells creating an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage PT3B
Have a diagnosis of pT3b, T4a or T4b melanoma on biopsy.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: oncolytic virus therapy
Lab requirements
Blood counts
Demonstrate adequate organ function. All screening labs should be performed within 30 days of treatment initiation.
Kidney function
Demonstrate adequate organ function. All screening labs should be performed within 30 days of treatment initiation.
Liver function
Demonstrate adequate organ function. All screening labs should be performed within 30 days of treatment initiation.
Demonstrate adequate organ function. All screening labs should be performed within 30 days of treatment initiation.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify